Does Obtaining a Diagnosis of Interstitial Cystitis/Bladder Pain Syndrome Improve Symptoms or Quality of Life? A Cross-Sectional Questionnaire-Based Study

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Katherine A. Volpe ◽  
Rachel Mandelbaum ◽  
Larissa V. Rodriguez ◽  
Begüm Z. Özel ◽  
Renee Rolston ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Cross Sectional ◽  
Bladder Pain

scholarly journals Sleep Disturbances and Nocturnal Symptoms: Relationships with Quality of Life in a Population-Based Sample of Women with Interstitial Cystitis/Bladder Pain Syndrome

2014 ◽  
Vol 10 (12) ◽  
pp. 1331-1337 ◽  
Author(s):  
Wendy M. Troxel ◽  
Marika Booth ◽  
Daniel J. Buysse ◽  
Marc N. Elliott ◽  
Anne M. Suskind ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Interstitial Cystitis ◽  
Sleep Disturbances ◽  
Pain Syndrome ◽  
Population Based ◽  
Bladder Pain Syndrome ◽  
Bladder Pain

scholarly journals Validation of a quality-of-life scale for women with bladder pain syndrome/interstitial cystitis

2011 ◽  
Vol 21 (9) ◽  
pp. 1665-1670 ◽  
Author(s):  
Laura M. Bogart ◽  
Marika J. Suttorp ◽  
Marc N. Elliott ◽  
J. Quentin Clemens ◽  
Sandra H. Berry
Keyword(s):  
Quality Of Life ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Quality Of Life Scale ◽  
Life Scale

scholarly journals Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome

2017 ◽  
Vol 4 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Vinaya Vasudevan ◽  
Robert Moldwin
Keyword(s):  
Quality Of Life ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain

scholarly journals MP47-18 SIMPLE CYSTECTOMY FOR FEMALE PATIENTS WITH REFRACTORY INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: IS THERE ANY LONG-TERM IMPACT ON QUALITY OF LIFE, BODY IMAGE, AND SEXUAL FUNCTION?

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Joao Zambon* ◽  
Kshipra Hemal ◽  
Robert Evans ◽  
Gopal Badlani ◽  
Steve Walker ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Body Image ◽  
Sexual Function ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Long Term Impact

scholarly journals Mirabegron to manage symptoms of interstitial cystitis / bladder pain syndrome: A stone for two birds?

2021 ◽  
pp. 020-023
Author(s):  
Pereira-Correia João Antonio ◽  
Nahoum Luiza Amaral ◽  
Aldred Pinto João Ernesto ◽  
Fernandes Muller Valter José
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Urinary Urgency ◽  
Urinary Frequency ◽  
Bladder Pain ◽  
Pain Symptoms

Background: Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) patients often experience lowered quality of life due to pain, urinary urgency, and increases in urinary frequency. Like many chronic pain disorders, IC/BPS is poorly understood and treatment unsatisfactory. Materials and methods: We prospectively monitored the effects on pain and urinary complaints, of mirabegron associated with amitriptyline, for randomly selected women with IC/BPS. Results: Twenty-five women were randomly selected to treat pain symptoms of IC/BPS and 12 followed up until the end of the study. All patients showed improvement on all questionnaires referring to pain IC/BPS symptoms and urinary storage symptoms. There was no statistically significant improvement in urinary frequency. Conclusions: We suggest that mirabegron can work controlling urinary urgency and pain of IC/BPS patients.

scholarly journals Health-related quality of life in patients with interstitial cystitis/bladder pain syndrome and frequently associated comorbidities

2012 ◽  
Vol 22 (7) ◽  
pp. 1537-1541 ◽  
Author(s):  
Anne M. Suskind ◽  
Sandra H. Berry ◽  
Marika J. Suttorp ◽  
Marc N. Elliott ◽  
Ron D. Hays ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Health Related Quality ◽  
Bladder Pain ◽  
Related Quality ◽  
Health Related

Bladder Pain: The Patient Perspective

2017 ◽  
Vol 84 (1_suppl) ◽  
pp. 5-7 ◽  
Author(s):  
Jane M. Meijlink
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Urinary Tract ◽  
Patient Perspective ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Practical Support ◽  
Tract Infections

Patients with chronic pain, discomfort and other urinary symptoms related to bladder pain syndrome or urinary tract infections may experience severely diminished quality of life and psychological and social problems, including depression, anxiety, and a sense of helplessness and hopelessness. These patients require empathy, understanding and practical support to allow them to cope with their chronic bladder disorder.

scholarly journals Retrospective Review of 5-Year Experience with Intravesical Injections of Bupivacaine, Triamcinalone and Gentamicin for Interstitial Cystitis/ Bladder Pain Syndrome

2020 ◽  
pp. 1-4
Author(s):  
Gupta Sandhya ◽  
◽  
Rane Ajay ◽  
Keyword(s):  
Interstitial Cystitis ◽  
Symptom Relief ◽  
Symptom Control ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
First Line ◽  
Treatment Delivery ◽  
Bladder Pain ◽  
Poor Efficacy

Objectives: Interstitial cystitis (IC) is a poorly diagnosed condition that produces chronic and painful symptoms that affect the sufferer’s quality of life. This article reports on the outcomes and trends of patients who received an intravesical cocktail injection of triamcinolone (steroid), gentamycin, and bupivacaine for symptom control in interstitial cystitis over a 5-year period. Methods: A retrospective analysis was performed on 408 patients with Interstitial Cystitis/Bladder Pain Syndrome who were treated with an intravesical cocktail injection (triamcinolone, gentamicin, and bupivacaine) over a 5-year period (Jan 2015 – Dec 2019). All patients had been diagnosed with IC/BPS and had received first-line treatment as per the American Urology Association IC/BPS Guidelines. The age of the patients, the number of treatments, and the duration between each treatment were analysed using Spearman’s rho analysis. Results: In our cohort of patients, 264 patients (64.7%) responded well to just one intravesical cocktail therapy, 93 patients (22.7%) required two treatments, and 51 patients (12.5%) required 3 or more treatments for their symptom control. The longest interval between treatment delivery was between the first and second dose, an average of 328.2 days. A trend of sequentially shorter intervals between injections was demonstrated in those patients who required more than one therapeutic injection. Conclusions: The majority of the cohort patients, 87.5%, responded well and found sufficient symptom relief from just one or two intravesical injections. However, patients who required repeated injections received them at progressively shorter intervals, signifying poor efficacy of symptom control in this subset of patients.

Sign in / Sign up

Export Citation Format

Share Document